Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 2Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1Cardiotoxicity 1

Interventions

Cyclophosphamide 56Etoposide 40Filgrastim 37Carboplatin 34Vincristine 30Doxorubicin 30Melphalan 27Topotecan 25Isotretinoin 24Peripheral Blood Stem Cell Transplantation 23Granulocyte Colony-Stimulating Factor 22Cisplatin 21Irinotecan 20sargramostim 18Temozolomide 17humanized 3F8 anti-GD2 monoclonal antibody 15Radiotherapy 153-Iodobenzylguanidine 13Granulocyte-Macrophage Colony-Stimulating Factor 11Busulfan 11dinutuximab 10Interleukin-2 9aldesleukin 8Thiotepa 8Ifosfamide 8etoposide phosphate 7Mesna 7Vorinostat 6Stem Cell Transplantation 6Polymerase Chain Reaction 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroblastoma × Fenofibrate × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡